Supporting people in hospitals across South Australia through vital health and medical research and improved patient care.
Meet our passionate and dedicated team.
Meet our Board and Governance team.
THRF adopts extremely high transparency standards when reporting our financials.
Supports research into the detection, management and treatment of breast cancer.
Funds vital medical research into the detection and treatment of prostate cancer, as well as preventing the metastatic spread of the disease.
We are passionate and determined to improve heart health and beat heart disease through advances in knowledge and research.
Our aim is to reduce and ultimately eliminate the high incidence of chronic kidney disease and diabetes in Australia and around the world.
Supports health and wellbeing research for veterans, emergency service personnel and their families.
Driving collaboration, innovation and research to develop best-practice arts, design and health programs.
Supporting world-class stroke research to improve prevention, diagnosis and acute treatment to cure stroke.
Do you want to join our team? Check out current career opportunities here.
View some of the commonly asked questions about our organisation.
We are so grateful to those who donate their time and skills to support life-changing medical research. Find out more…
Get in touch with us here.
Supported by The Hospital Research Foundation (THRF), Dr Ashish Shrestha’s research aims to develop a universal Hepatitis C virus vaccine and a DNA vaccine to provide effective protection against the Zika virus, currently there are no developed vaccines against either virus.
Hepatitis C is a blood-borne disease cause by Hepatitis C virus. The virus causes inflammation of the liver and can lead to carcinoma (a cancer that begins in liver and can spread to other parts of the body) and liver cirrhosis (liver damage).
Globally, more than 185 million people have been infected with the virus and estimated health care costs for the treatment is around $252 million per annum in Australia.
Zika is a disease contracted by an infected mosquito bite, which can cause fever, rash and muscle and joint pain. Aiming to develop vaccines against these viruses, Dr Shrestha’s background in microbiology will be a vital contribution to this research.
Awarded a THRF Early Career Fellowship, Dr Shrestha relocated to the Basil Hetzel Institute for Translational Health Research (BHI) in July from the University of Queensland to pursue this vital research. Dr Shrestha is working under Professor Eric Gowans who is leading this research.
“Prof Gowans has already developed a novel Hepatitis C DNA vaccine and I am researching to develop a vaccine which can protect against the four most common Hepatitis C virus genotypes found globally,” Dr Shrestha explained.
“I am also working on the development of a vaccine for the Zika virus. As the Zika virus belongs to the same family as the Hepatitis C virus I will be using a similar strategy to target it.”
“Although there are existing treatment methods for people who contract Hepatitis C, they are very expensive. The number of Hepatitis C cases in Australia is increasingly reported each year, so a new and cheaper vaccine is vital.”
Dr Shrestha’s potential Zika virus vaccine will be targeted to people living in tropical regions, travellers and also pregnant women, as mothers infected during pregnancy are more likely to have children with microcephaly (small brain syndrome) for which there is no treatment.
Dr Shrestha is grateful to THRF and the donor community for the opportunity to potentially develop new much-needed vaccines for these life threatening viruses.
“I am very grateful to THRF for supporting this great research that will save lives. I am also especially grateful for the donor community who have contributed these vital funds to provide researchers like myself the opportunity to develop treatment methods for diseases.”
Would you like to support medical research like Dr Ashish Shrestha’s?
We are pleased to announce Professor Eric Gowans, along with Dr Branka Grubor-Bauk and Dr Danushka Wijesundara at the Basil Hetzel Institute for Translational Health Research have received funding from the National Foundation for Medical Research and Innovation to examine new strategies to develop a vaccine for the dangerous Zika virus. read more
While plenty of people battle the common cold each year, scientists at the Basil Hetzel Institute for Translational Health Research believe it could lead to a defence against a much deadlier virus, HIV. read more
Currently affecting over 250 million people worldwide…can you imagine a world free of viruses such as HIV and Hepatitis C virus (HCV)? Dr Dan Wijesundara wants to contribute to eradicating these diseases. read more
Researchers are a step closer to developing a therapeutic vaccine for the deadly viruses HIV and Hepatitis C which could ultimately enable a cure for people suffering with these conditions. read more
A promising new study at The Basil Hetzel Institute and The Queen Elizabeth Hospital aims to develop a new therapeutic vaccine for patients with Hepatitis C (HCV). read more
The Hospital Research Foundation has funded an ELISpot Plate Reader for the Viral Immunology Group, to assist their vital research into Hepatitis C and HIV. read more
Congratulations to PhD student Tamsin Garrod, who was presented with the Robert Dixon Award at the recent Australian Conference of Hepatitis and HIV (ACH2). read more
Senior Research Fellow, Professor Eric Gowans, was the guest speaker at our latest Corporate Research Breakfast hosted in the impressive CMI Toyota showroom on West Terrace. read more